Brief Escalation of Adalimumab Treatment for Prevention of Clinical Relapse in IBD

Summary

To examine whether a temporary three month increase in adalimumab dosing will prevent relapse in patients with inflammatory bowel disease in clinical remission who have elevated calprotectin.

Timeline

Start

2018-02-01

Primary completion

2019-02-01

Completion

2019-09-01

Drugs

Indications